Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF)open access
- Authors
- Jung, Moonki; Byeon, Kyeongmin; Kang, Ki-Woon; Lee, Wang-Soo; Kim, Sang Wook; Park, Yae Min; Hwang, You Mi; Lee, Sung Ho; Jin, Eun-Sun; Roh, Seung-Young; Kim, Jin Seok; Ahn, Jinhee; Lee, So-Ryoung; Choi, Eue-Keun; Ahn, Min-Soo; Lee, Eun Mi; Park, Hwan-Cheol; Lee, Ki Hong; Kim, Min; Choi, Joon Hyouk; Ko, Jum Suk; Kim, Jin Bae; Kim, Changsoo; Lip, Gregory Y. H.; Shin, Seung Yong
- Issue Date
- Jun-2023
- Publisher
- WILEY
- Keywords
- ABCD score; antithrombotic treatment; atrial fibrillation; net clinical benefit; non-vitamin K antagonist oral anticoagulant
- Citation
- JOURNAL OF ARRHYTHMIA, v.39, no.3, pp.376 - 387
- Indexed
- SCOPUS
- Journal Title
- JOURNAL OF ARRHYTHMIA
- Volume
- 39
- Number
- 3
- Start Page
- 376
- End Page
- 387
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191040
- DOI
- 10.1002/joa3.12840
- ISSN
- 1880-4276
- Abstract
- BackgroundThe balance of stroke risk reduction and potential bleeding risk associated with antithrombotic treatment (ATT) remains unclear in atrial fibrillation (AF) at non-gender CHA(2)DS(2)-VASc scores 0-1. A net clinical benefit (NCB) analysis of ATT may guide stroke prevention strategies in AF with non-gender CHA(2)DS(2)-VASc scores 0-1. MethodsThis multi-center cohort study evaluated the clinical outcomes of treatment with a single antiplatelet (SAPT), vitamin K antagonist (VKA), and non-VKA oral anticoagulant (NOAC) in non-gender CHA(2)DS(2)-VASc score 0-1 and further stratified by biomarker-based ABCD score (Age [>= 60 years], B-type natriuretic peptide [BNP] or N-terminal pro-BNP [>= 300 pg/mL], creatinine clearance [<50 mL/min], and dimension of the left atrium [>= 45 mm]). The primary outcome was the NCB of ATT, including composite thrombotic events (ischemic stroke, systemic embolism, and myocardial infarction) and major bleeding events. ResultsWe included 2465 patients (age 56.2 +/- 9.5 years; female 27.0%) followed-up for 4.0 +/- 2.8 years, of whom 661 (26.8%) were treated with SAPT; 423 (17.2%) with VKA; and 1040 (42.2%) with NOAC. With detailed risk stratification using the ABCD score, NOAC showed a significant positive NCB compared with the other ATTs (SAPT vs. NOAC, NCB 2.01, 95% confidence interval [CI] 0.37-4.66; VKA vs. NOAC, NCB 2.38, 95% CI 0.56-5.40) in ABCD score >= 1. ATT failed to show a positive NCB in patients with truly low stroke risk (ABCD score = 0). ConclusionsIn the Korean AF cohort at non-gender CHA(2)DS(2)-VASc scores 0-1, NOAC showed significant NCB advantages over VKA or SAPT with ABCD score >= 1.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191040)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.